Peripartum cardiomyopathy: Analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1

Journal of the American College of Cardiology

Volumn 35, Issue 3, 2000, Pages 701-705

  Sliwa, Karen ^a,b   Skudicky, Daniel ^a   Bergemann, Anette ^a,b   Candy, Geoffrey ^a,b   Puren, Adrian ^b   Sareli, Pinhas ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYTOKINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FAS ANTIGEN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DEATH; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; NEGRO; PRIORITY JOURNAL; PROGNOSIS; PUERPERIUM; SURVIVAL; THIRD TRIMESTER PREGNANCY; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD95; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CYTOKINES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; POSTPARTUM PERIOD; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; VENTRICULAR FUNCTION, LEFT;

EID: 0034163894     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00624-5     Document Type: Article

References (26)

1. Lampert M., Lang R.M. Peripartum cardiomyopathy. Am Heart J. 130:1995;860-870.
2. Homans D.C. Peripartum cardiomyopathy. N Engl J Med. 312:1985;1432-1437.
3. Sanderson J.E., Adesanya C.O., Anjorin F.I., Parry E.O. Postpartum cardiac failure heart failure due to volume overload . Am Heart J. 97:1979;613-621.
4. Seftel H., Susser M. Maternity and myocardial failure in African women. Br Heart J. 23:1961;43-52.
5. Demakis J.G., Rahimtoola S.H., Sutton G.C., et al. Natural course of peripartum cardiomyopathy. Circulation. 44:1971;1053-1061.
6. Meadows W.R. Idiopathic myocardial failure in the last trimester of pregnancy and the puerperium. Circulation. 15:1957;903-914.
7. Habib F.M., Springall D.R., Davies G.J., Oakley C.M., Yacoub M.H., Polak J.M. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet. 347:1996;1151-1155.
8. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction a report from the studies of left ventricular dysfunction (SOLVD) . J Am Coll Cardiol. 27:1996;1201-1206.
9. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
10. Narula J., Haider N., Virmani R., et al. Apoptosis in myocytes in end stage heart failure. N Engl J Med. 335:1996;1182-1189.
11. Olivetti G., Abbi R., Quaini F., et al. Apoptosis in the failing human heart. N Engl J Med. 336:1994;1131-1141.
12. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
13. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M.E. Apoptosis signaling by death receptors. Eur J Biochem. 254:1998;439-459.
14. Nishigaki K., Minatogushi S., Seishima M., et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol. 1997;1214-1220.
15. Sahn D.J., DeMaria A., Kisslo J., Weyman A. The Committee on M-mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography results of a survey of echocardiographic measurements . Circulation. 58:1978;1072-1083.
16. Quinones M.A., Pickering E., Alexander J.K. Percentage of shortening of the echocardiographic left ventricular dimension its use in determining ejection fraction and stroke volume . Chest. 74:1978;59-65.
17. Giannuzzi P., Temporelli P.L., Bosimini E., et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol. 28:1996;383-390.
18. Hadjimitiades S., Panidis I.P., Segal B.L., Iskandrian A.S. Recovery of left ventricular function in peripartum cardiomyopathy. Am Heart J. 112:1986;1097-1103.
19. Midei M., DeMent S., Feldman A., Hutchins G., Baughman K. Peripartum myocarditis and cardiomyopathy. Circulation. 81:1990;922-928.
20. Van Hoevan K.H., Kitsis R.N., Katz S.D., Factor S.M. Peripartum versus idiopathic dilated cardiomyopathy in young women - a comparison of clinical, pathological and prognostic features. Int J Cardiol. 40:1993;57-65.
21. Ravikishore A.G., Kaul U.A., Sethi K.K., Khalilullah M. Peripartum cardiomyopathy prognostic variables at initial evaluation . Int J Cardiol. 32:1991;377-387.
22. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 92:1995;1479-1486.
23. Belder A., Radomski M., Why H., Richardson P., Martin J. Myocardial calcium-independent nitric oxide synthase activity is present in dilated cardiomyopathy, myocarditis and postpartum cardiomyopathy but not in ischemic or valvular heart disease. Br Heart J. 74:1995;426-430.
24. Schieffer B., Kowert A., Brauer N., et al. Irbesartan inhibits angiotensin II induced proinflammatory and prothrombotic factors in human coronary arteries role of the Jak/STAT case (abstr) . Eur Heart J. 19:1998;S-14.
25. Kerr J.F.R. Shrinage necrosis a distinct mode of cellular death . J Pathol. 105:1971;13-21.
26. Kerr J.F.R., Wyllie A.H., Currie A.R. Apoptosis a basic biological phenomenon with wide ranging implications in tissue kinetics . Br J Cancer. 26:1972;239-257.